The Challenge
Meridian Health had spent three years building a remote patient monitoring platform with genuine clinical validation — but when it came time to raise their Series A, the founding team were clinicians, not dealmakers. They had the product and the data. They needed someone to help them speak the language of institutional investors.
Azimuth came in six months before the target close date with a clear mandate: sharpen the narrative, stress-test the financials, and run a disciplined process.
What We Did
Narrative & positioning. We worked closely with the CEO and CMO to translate complex clinical outcomes into a crisp investor story. The core insight was reframing Meridian not as a hardware company but as a recurring-revenue data business with a defensible clinical moat.
Financial modelling. We rebuilt the five-year model from the ground up, introducing cohort-based revenue projections and scenario analysis that gave lead investors the confidence they needed to move quickly.
Investor targeting & process management. We helped identify and prioritise a shortlist of 22 VCs with genuine health-tech conviction. We ran a structured four-week process with parallel conversations, keeping momentum high and preventing any single investor from setting the pace.
“Azimuth didn’t just open doors — they helped us walk through them prepared. The difference between our first investor meetings and our final term-sheet negotiation was night and day.”
— CEO, Meridian Health
The Outcome
Meridian closed a £4.2 million Series A led by a specialist health-tech fund, with two strategic co-investors from the NHS innovation ecosystem. The round was oversubscribed within the target window.
Azimuth retains a small equity position and continues to advise the board on subsequent financing strategy.
Key Takeaways
- Clinical validation alone does not close institutional rounds — the narrative must connect outcomes to commercial value
- A structured, time-bounded process creates competitive dynamics that protect founder leverage
- Investors respond to preparation; thorough due-diligence materials cut weeks off the close timeline